Heart and Vessels

, Volume 34, Issue 1, pp 19–28 | Cite as

Association between plasma levels of PCSK9 and the presence of coronary artery disease in Japanese

  • Daisuke Nose
  • Yuhei Shiga
  • Yoko Ueda
  • Yoshiaki Idemoto
  • Kohei Tashiro
  • Yasusnori Suematsu
  • Takashi Kuwano
  • Ken Kitajima
  • Keijiro Saku
  • Shin-ichiro MiuraEmail author
Original Article


The ability of pro-protein convertase subtilisin/kexin type 9 (PCSK9) levels to predict the presence or severity of coronary artery disease (CAD) remains controversial. The purpose of this study was to investigate these associations. We enrolled 393 patients who were clinically suspected to have CAD or who had at least one cardiac risk factor and underwent multidetector-row computed tomography coronary angiography. The presence of CAD (≥50% coronary stenosis), the number of significantly stenosed coronary vessels, and plasma levels of PCSK9 by ELISA were analyzed. Plasma PCSK9 levels (log-transformed data) were significantly associated with the presence of CAD. Next, we divided the patients into two groups (non-statin and statin groups) according to statin treatment. PCSK9 levels in the non-statin group were significantly lower than those in the statin group. There were no significant differences in PCSK9 levels between the absence and presence of CAD in the statin group. However, in the non-statin group, PCSK9 levels in patients with CAD were significantly higher than those in patients without CAD. PCSK9 levels, in addition to age, gender, BMI, DM and HDL-C, were independently associated with the presence of CAD by a multivariable analysis. In conclusion, our results demonstrated that plasma PCSK9 levels may be a marker for evaluating the presence of CAD.


Pro-protein convertase subtilisin/kexin type 9 Coronary artery disease Multidetector-row computed tomography Statin 


Compliance with ethical standards

Conflict of interest

KS and SM are Directors of NPO Clinical and Applied Science, Fukuoka, Japan. KS and SM received a grant from the Public Interest Incorporated Foundation of “Clinical Research Promotion Foundation” in Fukuoka, Japan, and part of this work was transferred to NPO Clinical and Applied Science, Fukuoka, Japan. KS has an Endowed Department of Molecular Cardiovascular Therapeutics (SM), Fukuoka University, supported by MSD Co., Ltd.


  1. 1.
    Lambert G, Sjouke B, Choque B, Kastelein JJ, Hovingh GK (2012) The PCSK9 decade. J Lipid Res 53:2515–2524CrossRefGoogle Scholar
  2. 2.
    Sun H, Samarghandi A, Zhang N, Yao Z, Xiong M, Teng BB (2012) Proprotein convertase subtilisin/kexin type 9 interacts with apolipoprotein B and prevents its intracellular degradation, irrespective of the low-density lipoprotein receptor. Arterioscler Thromb Vasc Biol 32:1585–1595CrossRefGoogle Scholar
  3. 3.
    Le May C, Kourimate S, Langhi C, Chetiveaux M, Jarry A, Comera C, Collet X, Kuipers F, Krempf M, Cariou B, Costet P (2009) Proprotein convertase subtilisin kexin type 9 null mice are protected from postprandial triglyceridemia. Arterioscler Thromb Vasc Biol 29:684–690CrossRefGoogle Scholar
  4. 4.
    Maxwell KN, Breslow JL (2004) Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype. Proc Natl Acad Sci USA 101:7100–7105CrossRefGoogle Scholar
  5. 5.
    Welder G, Zineh I, Pacanowski MA, Troutt JS, Cao G, Konrad RJ (2010) High-dose atorvastatin causes a rapid sustained increase in human serum PCSK9 and disrupts its correlation with LDL cholesterol. J Lipid Res 51:2714–2721CrossRefGoogle Scholar
  6. 6.
    Sahebkar A, Simental-Mendia LE, Guerrero-Romero F, Golledge J, Watts GF (2015) Effect of statin therapy on plasma proprotein convertase subtilisin kexin 9 (PCSK9) concentrations: a systematic review and meta-analysis of clinical trials. Diabetes Obes Metab 17:1042–1055CrossRefGoogle Scholar
  7. 7.
    Nozue T (2017) Lipid lowering therapy and circulating PCSK9 concentration. J Atheroscler Thromb 24:895–907CrossRefGoogle Scholar
  8. 8.
    Cohen JC, Boerwinkle E, Mosley THJr, Hobbs HH (2006) Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med 354:1264–1272CrossRefGoogle Scholar
  9. 9.
    Benn M, Nordestgaard BG, Grande P, Schnohr P, Tybjaerg-Hansen A (2010) PCSK9 R46L, low-density lipoprotein cholesterol levels, and risk of ischemic heart disease: 3 independent studies and meta-analyses. J Am Coll Cardiol 55:2833–2842CrossRefGoogle Scholar
  10. 10.
    Li S, Guo YL, Xu RX, Zhang Y, Zhu CG, Sun J, Qing P, Wu NQ, Li JJ (2014) Plasma PCSK9 levels are associated with the severity of coronary stenosis in patients with atherosclerosis. Int J Cardiol 174:863–864CrossRefGoogle Scholar
  11. 11.
    Li S, Zhang Y, Xu RX, Guo YL, Zhu CG, Wu NQ, Qing P, Liu G, Dong Q, Li JJ (2015) Proprotein convertase subtilisin-kexin type 9 as a biomarker for the severity of coronary artery disease. Ann Med 47:386–393CrossRefGoogle Scholar
  12. 12.
    Li JJ, Li S, Zhang Y, Xu RX, Guo YL, Zhu CG, Wu NQ, Qing P, Gao Y, Sun J, Liu G, Dong Q (2015) Proprotein convertase subtilisin/kexin type 9, C-reactive protein, coronary severity, and outcomes in patients with stable coronary artery disease: a prospective observational cohort study. Med (Baltim) 94:e2426CrossRefGoogle Scholar
  13. 13.
    Zhu YM, Anderson TJ, Sikdar K, Fung M, McQueen MJ, Lonn EM, Verma S (2015) Association of proprotein convertase subtilisin/kexin type 9 (PCSK9) with cardiovascular risk in primary prevention. Arterioscler Thromb Vasc Biol 35:2254–2259CrossRefGoogle Scholar
  14. 14.
    Ridker PM, Rifai N, Bradwin G, Rose L (2016) Plasma proprotein convertase subtilisin/kexin type 9 levels and the risk of first cardiovascular events. Eur Heart J 37:554–560CrossRefGoogle Scholar
  15. 15.
    Leander K, Malarstig A, Van’t Hooft FM, Hyde C, Hellenius ML, Troutt JS, Konrad RJ, Ohrvik J, Hamsten A, de Faire U (2016) Circulating proprotein convertase subtilisin/kexin type 9 (PCSK9) predicts future risk of cardiovascular events independently of established risk factors. Circulation 133:1230–1239CrossRefGoogle Scholar
  16. 16.
    Zheng Y, Ma W, Zeng Y, Liu J, Ye S, Chen S, Lan L, Erbel R, Liu Q (2010) Comparative study of clinical characteristics between Chinese Han and German Caucasian patients with coronary heart disease. Clin Res Cardiol 99:45–50CrossRefGoogle Scholar
  17. 17.
    Gijsberts CM, den Ruijter HM, Asselbergs FW, Chan MY, de Kleijn DP, Hoefer IE (2015) Biomarkers of coronary artery disease differ between Asians and Caucasians in the general population. Glob Heart 10(301–311):e11Google Scholar
  18. 18.
    Verschuren WM, Jacobs DR, Bloemberg BP, Kromhout D, Menotti A, Aravanis C, Blackburn H, Buzina R, Dontas AS, Fidanza F, Karvonen MJ, Nedelijkovic SM, Nissinen A, Toshima H (1995) Serum total cholesterol and long-term coronary heart disease mortality in different cultures. Twenty-five-year follow-up of the seven countries study. JAMA 274:131–136CrossRefGoogle Scholar
  19. 19.
    Mitsutake R, Niimura H, Miura S, Zhang B, Iwata A, Nishikawa H, Kawamura A, Kumagai K, Shirai K, Matsunaga A, Saku K (2006) Clinical significance of the coronary calcification score by multidetector row computed tomography for the evaluation of coronary stenosis in Japanese patients. Circ J 70:1122–1127CrossRefGoogle Scholar
  20. 20.
    Dodge JTJ, Brown BG, Bolson EL, Dodge HT (1988) Intrathoracic spatial location of specified coronary segments on the normal human heart. Applications in quantitative arteriography, assessment of regional risk and contraction, and anatomic display. Circulation 78:1167–1180CrossRefGoogle Scholar
  21. 21.
    Sinning C, Lillpopp L, Appelbaum S, Ojeda F, Zeller T, Schnabel R, Lubos E, Jagodzinski A, Keller T, Munzel T, Bickel C, Blankenberg S (2013) Angiographic score assessment improves cardiovascular risk prediction: the clinical value of SYNTAX and Gensini application. Clin Res Cardiol 102:495–503CrossRefGoogle Scholar
  22. 22.
    Patel SS, Kimmel PL, Singh A (2002) New clinical practice guidelines for chronic kidney disease: a framework for K/DOQI. Semin Nephrol 22:449–458CrossRefGoogle Scholar
  23. 23.
    Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, Yamagata K, Tomino Y, Yokoyama H, Hishida A (2009) Revised equations for estimated GFR serum creatinine in Japan. Am J Kidney Dis 53:982–992CrossRefGoogle Scholar
  24. 24.
    Wang S, Cheng ZY, Zhao ZN, Quan XQ, Wei Y, Xia DS, Li JQ, Hu JL (2016) Correlation of serum PCSK9 in CHD patients with the severity of coronary arterial lesions. Eur Rev Med Pharmacol Sci 20:1135–1139Google Scholar
  25. 25.
    Zhao X, Zhang HW, Li S, Zhang Y, Xu RX, Zhu CG, Wu NQ, Guo YL, Qing P, Li XL, Liu G, Dong Q, Sun J, Li JJ (2018) Association between plasma proprotein convertase subtilisin/kexin type 9 concentration and coronary artery calcification. Ann Clin Biochem 55:158–164CrossRefGoogle Scholar
  26. 26.
    Chan DC, Pang J, McQuillan BM, Hung J, Beilby JP, Barrett PH, Watts GF (2016) Plasma proprotein convertase subtilisin kexin type 9 as a predictor of carotid atherosclerosis in asymptomatic adults. Heart Lung Circ 25:520–525CrossRefGoogle Scholar
  27. 27.
    Careskey HE, Davis RA, Alborn WE, Troutt JS, Cao G, Konrad RJ (2008) Atorvastatin increases human serum levels of proprotein convertase subtilisin/kexin type 9. J Lipid Res 49:394–398CrossRefGoogle Scholar
  28. 28.
    Dong B, Wu M, Li H, Kraemer FB, Adeli K, Seidah NG, Park SW, Liu J (2010) Strong induction of PCSK9 gene expression through HNF1alpha and SREBP2: mechanism for the resistance to LDL-cholesterol lowering effect of statins in dyslipidemic hamsters. J Lipid Res 51:1486–1495CrossRefGoogle Scholar
  29. 29.
    Maxwell KN, Soccio RE, Duncan EM, Sehayek E, Breslow JL (2003) Novel putative SREBP and LXR target genes identified by microarray analysis in liver of cholesterol-fed mice. J Lipid Res 44:2109–2119CrossRefGoogle Scholar
  30. 30.
    Almontashiri NA, Vilmundarson RO, Ghasemzadeh N, Dandona S, Roberts R, Quyyumi AA, Chen HH, Stewart AF (2014) Plasma PCSK9 levels are elevated with acute myocardial infarction in two independent retrospective angiographic studies. PLoS One 9:e106294CrossRefGoogle Scholar
  31. 31.
    Hu D, Yang Y, Peng DQ (2017) Increased sortilin and its independent effect on circulating proprotein convertase subtilisin/kexin type 9 (PCSK9) in statin-naive patients with coronary artery disease. Int J Cardiol 227:61–65CrossRefGoogle Scholar
  32. 32.
    Simons LA (1986) Interrelations of lipids and lipoproteins with coronary artery disease mortality in 19 countries. Am J Cardiol 57:5G–10GCrossRefGoogle Scholar
  33. 33.
    Iso H (2011) Lifestyle and cardiovascular disease in Japan. J Atheroscler Thromb 18:83–88CrossRefGoogle Scholar
  34. 34.
    Pristipino C, Beltrame JF, Finocchiaro ML, Hattori R, Fujita M, Mongiardo R, Cianflone D, Sanna T, Sasayama S, Maseri A (2000) Major racial differences in coronary constrictor response between japanese and caucasians with recent myocardial infarction. Circulation 101:1102–1108CrossRefGoogle Scholar
  35. 35.
    Zhang Y, Wu NQ, Li S, Zhu CG, Guo YL, Qing P, Gao Y, Li XL, Liu G, Dong Q, Li JJ (2016) Non-HDL-C is a better predictor for the severity of coronary atherosclerosis compared with LDL-C. Heart Lung Circ 25:975–981CrossRefGoogle Scholar
  36. 36.
    Ke D, Chen Q, Wu Q, Li X, Wu Z, Li G, Deng W, Mo X (2011) Analysis of the correlation between non-high density lipoprotein cholesterol and coronary heart disease in elderly Chinese. Intern Med 50:1279–1285CrossRefGoogle Scholar
  37. 37.
    Nishigaki K, Yamazaki T, Fukunishi M, Tanihata S, Fujiwara H, Group (2004) JCIS. Assessment of acute myocardial infarction in Japan by the Japanese coronary intervention study (JCIS) group. Circ J 68:515–519CrossRefGoogle Scholar
  38. 38.
    Mitsutake R, Miura S, Shiga Y, Uehara Y, Saku K (2011) Association between hypertension and coronary artery disease as assessed by coronary computed tomography. J Clin Hypertens (Greenwich) 13:198–204CrossRefGoogle Scholar
  39. 39.
    Cheng JM, Oemrawsingh RM, Garcia-Garcia HM, Boersma E, van Geuns RJ, Serruys PW, Kardys I, Akkerhuis KM (2016) PCSK9 in relation to coronary plaque inflammation: results of the ATHEROREMO-IVUS study. Atherosclerosis 248:117–122CrossRefGoogle Scholar
  40. 40.
    Ding Z, Liu S, Wang X, Deng X, Fan Y, Shahanawaz J, Shmookler Reis RJ, Varughese KI, Sawamura T, Mehta JL (2015) Cross-talk between LOX-1 and PCSK9 in vascular tissues. Cardiovasc Res 107:556–567CrossRefGoogle Scholar
  41. 41.
    Navarese EP, Kolodziejczak M, Dimitroulis D, Wolff G, Busch HL, Devito F, Sionis A, Ciccone MM (2016) From proprotein convertase subtilisin/kexin type 9 to its inhibition: state-of-the-art and clinical implications. Eur Heart J Cardiovasc Pharmacother 2:44–53CrossRefGoogle Scholar
  42. 42.
    Fine JJ, Hopkins CB, Ruff N, Newton FC (2006) Comparison of accuracy of 64-slice cardiovascular computed tomography with coronary angiography in patients with suspected coronary artery disease. Am J Cardiol 97:173–174CrossRefGoogle Scholar
  43. 43.
    Lakoski SG, Lagace TA, Cohen JC, Horton JD, Hobbs HH (2009) Genetic and metabolic determinants of plasma PCSK9 levels. J Clin Endocrinol Metab 94:2537–2543CrossRefGoogle Scholar

Copyright information

© Springer Japan KK, part of Springer Nature 2018

Authors and Affiliations

  • Daisuke Nose
    • 1
  • Yuhei Shiga
    • 1
  • Yoko Ueda
    • 1
  • Yoshiaki Idemoto
    • 1
  • Kohei Tashiro
    • 1
  • Yasusnori Suematsu
    • 1
  • Takashi Kuwano
    • 1
  • Ken Kitajima
    • 1
  • Keijiro Saku
    • 1
    • 2
  • Shin-ichiro Miura
    • 1
    • 2
    Email author
  1. 1.Department of CardiologyFukuoka University School of MedicineFukuokaJapan
  2. 2.Department of Molecular Cardiovascular TherapeuticsFukuoka University School of MedicineFukuokaJapan

Personalised recommendations